Prohost BiotechResearch Platform

Home Articles Today's HighlightsIllumina: Good News! Private Lessons. JAZZ: A New High. Upgrades and Downgrades. The Plummeting of Questor and More

Today's Highlights

Premium

Illumina: Good News! Private Lessons. JAZZ: A New High. Upgrades and Downgrades. The Plummeting of Questor and More

ILLUMINA (ILMN) We heard good news in three announcements made by Illumina (ILMN) this week. The first was about marketing Illunina’s TruSeq® Stranded mRNA and Total RNA Sample Preparation Kits...

P

Prohost Biotech

September 20, 2012

1 min read

17

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

Achillion Pharmaceuticals (ACHN)

Ariad Pharmaceuticals (ARIA)

Celldex Therapeutics (CLDX)

Gilead Sciences (GILD)

Illumina (ILMN)

Jazz Pharmaceuticals (JAZZ)

Life Technologies (LIFE)

Questcor Pharmaceuticals (QCOR)

Regeneron Pharmaceuticals (REGN)

Seagen Inc (SGEN)

Comments (0)

Please sign in to join the discussion

Related Articles

Today's Highlights

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...

Prohost Biotech

Mar 31, 2026

Today's Highlights

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today, March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...

Prohost Biotech

Mar 30, 2026

Today's Highlights

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...

Prohost Biotech

Mar 27, 2026